{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:14:13Z","timestamp":1794366853486,"version":"4.9.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004870","name":"University of M\u00fcnster Faculty of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004870","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1053\/j.semnuclmed.2026.03.004","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T08:30:14Z","timestamp":1775032214000},"page":"748-758","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The prostatic acid phosphatase in prostate cancer: A novel theranostic target"],"prefix":"10.1053","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9109-9004","authenticated-orcid":false,"given":"Konstantin Egon","family":"Seifert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julissa","family":"Reimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8903-1913","authenticated-orcid":false,"given":"Martin","family":"Rust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"B\u00f6gemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres Jan","family":"Schrader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sch\u00e4fers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Bernemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Backhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.semnuclmed.2026.03.004_bib0001","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.03.004_bib0002","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1053\/j.semnuclmed.2026.03.004_bib0003","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","article-title":"F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients","volume":"44","author":"Giesel","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1053\/j.semnuclmed.2026.03.004_bib0004","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on prostate Cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"issue":"12","key":"10.1053\/j.semnuclmed.2026.03.004_bib0005","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.03.004_bib0006","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/modpathol.2014.77","article-title":"Comparison of different prostatic markers in lymph node and distant metastases of prostate cancer","volume":"28","author":"Queisser","year":"2015","journal-title":"Mod Pathol"},{"issue":"10276","key":"10.1053\/j.semnuclmed.2026.03.004_bib0007","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.03.004_bib0008","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1053\/j.semnuclmed.2025.11.025","article-title":"Therapy strategies to defeat prostate cancer heterogeneity","volume":"56","author":"Jadvar","year":"2026","journal-title":"Semin Nucl Med"},{"issue":"10","key":"10.1053\/j.semnuclmed.2026.03.004_bib0009","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.2967\/jnumed.117.191395","article-title":"Targeted a-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding","volume":"58","author":"Kratochwil","year":"2017","journal-title":"J Nucl Med"},{"issue":"2","key":"10.1053\/j.semnuclmed.2026.03.004_bib0010","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/j.semnuclmed.2020.02.004","article-title":"225Ac-PSMA-617 for therapy of prostate cancer","volume":"50","author":"Kratochwil","year":"2020","journal-title":"Semin Nucl Med"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.03.004_bib0011","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Penson","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.03.004_bib0012","first-page":"88","article-title":"Cellular prostatic acid phosphatase, a PTEN-functional homologue in prostate epithelia, functions as a prostate-specific tumor suppressor","volume":"1846","author":"Muniyan","year":"2014","journal-title":"Biochim Biophys Acta"},{"issue":"20","key":"10.1053\/j.semnuclmed.2026.03.004_bib0013","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.3390\/diagnostics13203242","article-title":"Diagnostic role and prognostic impact of PSAP immunohistochemistry: a tissue microarray study on 31,358 cancer tissues","volume":"13","author":"Tribian","year":"2023","journal-title":"Diagnostics"},{"issue":"4","key":"10.1053\/j.semnuclmed.2026.03.004_bib0014","first-page":"290","article-title":"Generation and characterization of novel high-affinity fully human antibodies targeting prostate-specific membrane antigen and prostatic acid phosphatase","volume":"8","author":"Comacchio","year":"2025","journal-title":"Antib Ther"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.03.004_bib0015","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41551-025-01432-6","article-title":"Discovery of high-affinity ligands for prostatic acid phosphatase via DNA-encoded library screening enables targeted cancer therapy","volume":"10","author":"Georgiev","year":"2026","journal-title":"Nat Biomed Eng"},{"key":"10.1053\/j.semnuclmed.2026.03.004_bib0016","doi-asserted-by":"crossref","unstructured":"Backhaus P, Cazzamalli S, Oehler S, et al. Translational and first-in-Human positron emission tomography targeting prostatic acid phosphatase in prostate cancer using the Ligand [68Ga]Ga-OncoACP3-DOTA. Eur Urol 2025:S0302-2838(25)04848-1. https:\/\/doi.org\/10.1016\/j.eururo.2025.11.025","DOI":"10.1016\/j.eururo.2025.11.025"},{"key":"10.1053\/j.semnuclmed.2026.03.004_bib0017","series-title":"J Nucl Med","article-title":"Dynamics, pharmacokinetics, and dosimetry of first-in-Human [68Ga]Ga-OncoACP3-DOTA PET in prostate cancer patients","author":"Brosch-Lenz","year":"2026"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.03.004_bib0018","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4062\/biomolther.2012.095","article-title":"Emerging roles of human prostatic acid phosphatase","volume":"21","author":"Kong","year":"2013","journal-title":"Biomol Ther (Seoul)"},{"key":"10.1053\/j.semnuclmed.2026.03.004_bib0019","doi-asserted-by":"crossref","unstructured":"Derechina M, Ostrowski W, Galkac M, et al. Acid phosphomonoesterase of human prostate molecular weight, dossociation and chemical composistion. 1971;250(1):143-154.","DOI":"10.1016\/0005-2744(71)90128-8"},{"issue":"1","key":"10.1053\/j.semnuclmed.2026.03.004_bib0020","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0005-2795(74)90008-7","article-title":"Subunit structure of human prostatic acid phosphatase","volume":"365","author":"Luchter-Wasyl","year":"1974","journal-title":"Biochim Biophys Aeta"},{"key":"10.1053\/j.semnuclmed.2026.03.004_bib0021","doi-asserted-by":"crossref","unstructured":"Zelivianski S, Comeau D, Lin MF. Cloning and Analysis of the Promoter Activity of the Human Prostatic Acid Phosphatase Gene 245(1):108-12, 1998.","DOI":"10.1006\/bbrc.1998.8386"},{"issue":"31","key":"10.1053\/j.semnuclmed.2026.03.004_bib0022","doi-asserted-by":"crossref","first-page":"23598","DOI":"10.1074\/jbc.M109.098301","article-title":"Human prostatic acid phosphatase, an authentic tyrosine phosphatase, dephosphorylates ErbB-2 and regulates prostate cancer cell growth","volume":"285","author":"Der","year":"2010","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1053\/j.semnuclmed.2026.03.004_bib0023","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s10585-013-9625-2","article-title":"Prostate cancer derived prostatic acid phosphatase promotes an osteoblastic response in the bone microenvironment","volume":"31","author":"Larson","year":"2014","journal-title":"Clin Exp Metastasis"},{"key":"10.1053\/j.semnuclmed.2026.03.004_bib0024","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0022-5347(05)65725-4","article-title":"Decreased expression of cellular prostatic acid phophatase increases tumorigenicity of human prostate cancer cells","volume":"166","author":"Lin","year":"2001","journal-title":"J Urol"},{"key":"10.1053\/j.semnuclmed.2026.03.004_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2023.1327769","article-title":"Elusive physiological role of prostatic acid phosphatase (PAP): generation of choline for sperm motility via auto-and paracrine cholinergic signaling","volume":"14","author":"Hanley","year":"2023","journal-title":"Front Physiol"},{"key":"10.1053\/j.semnuclmed.2026.03.004_bib0026","doi-asserted-by":"crossref","unstructured":"Seamonds B, Whitaker B, Norman Yang M, et al. Evaluation of prostate-specific antigen and prostatic acid phosphatase as prostate cancer markers. Urology 28(6):472-9, 1986. https:\/\/doi.org\/10.1016\/0090-4295(86)90146-9","DOI":"10.1016\/0090-4295(86)90146-9"},{"key":"10.1053\/j.semnuclmed.2026.03.004_bib0027","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/5687212","article-title":"Biomarkers of prostatic cancer: an attempt to categorize patients into prostatic carcinoma, benign prostatic hyperplasia, or prostatitis based on serum prostate specific antigen, prostatic acid phosphatase, calcium, and phosphorus","volume":"2017","author":"Sarwar","year":"2017","journal-title":"Prostate Cancer"},{"issue":"6","key":"10.1053\/j.semnuclmed.2026.03.004_bib0028","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/j.juro.2006.08.019","article-title":"The discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostate","volume":"176","author":"Makarov","year":"2006","journal-title":"J Urol"},{"issue":"9","key":"10.1053\/j.semnuclmed.2026.03.004_bib0029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0073072","article-title":"Transmembrane prostatic acid phosphatase (TMPAP) interacts with snapin and deficient mice develop prostate adenocarcinoma","volume":"8","author":"Quintero","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.03.004_bib0030","doi-asserted-by":"crossref","first-page":"255","DOI":"10.62347\/DZIU5992","article-title":"Transmembrane prostatic acid phosphatase: a therapeutic target in advanced prostate cancer","volume":"12","author":"Kirschenbaum","year":"2024","journal-title":"Am J Clin Exp Urol"},{"issue":"11","key":"10.1053\/j.semnuclmed.2026.03.004_bib0031","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1158\/1535-7163.MCT-23-0843","article-title":"Dual A2A\/A2B adenosine receptor antagonist M1069 counteracts immunosuppressive mechanisms of adenosine and reduces tumor growth In vivo","volume":"23","author":"Schiemann","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"10.1053\/j.semnuclmed.2026.03.004_bib0032","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/pros.2990120105","article-title":"Three predominant proteins secreted by the Human prostate gland","volume":"12","author":"Lilja","year":"1988","journal-title":"Prostate"},{"key":"10.1053\/j.semnuclmed.2026.03.004_bib0033","doi-asserted-by":"crossref","unstructured":"Hoyhtya M, Vihko P, Vuolas L, et al. High-affinity monoclonal antibodies specific for human prostatic acid phosphatase. 33(1):103-7, 1987. https:\/\/academic.oup.com\/clinchem\/article\/33\/1\/103\/5653078","DOI":"10.1093\/clinchem\/33.1.103"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.03.004_bib0034","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S0022-5347(17)49271-8","article-title":"Immunocytochemical demonstration of prostatic acid phosphatase: different secretion kinetics between normal, hyperplastic and neoplastic prostates","volume":"133","author":"Mori","year":"1985","journal-title":"J Urol"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.03.004_bib0035","first-page":"295","article-title":"Prostatic acid phosphatase expression in human tissues","volume":"4","author":"Graddis","year":"2011","journal-title":"Int J Clin Exp Pathol"},{"issue":"14","key":"10.1053\/j.semnuclmed.2026.03.004_bib0036","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1158\/0008-5472.CAN-07-1651","article-title":"Prostatic acid phosphatase is not a prostate specific target","volume":"67","author":"Quintero","year":"2007","journal-title":"Cancer Res"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.03.004_bib0037","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/pros.24104","article-title":"Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted \u03b2-emitting radionuclide therapies in metastatic castration-resistant prostate cancer","volume":"81","author":"Vlachostergios","year":"2021","journal-title":"Prostate"},{"issue":"3","key":"10.1053\/j.semnuclmed.2026.03.004_bib0038","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s11307-016-0942-0","article-title":"Lacrimal glands may represent organs at risk for radionuclide therapy of prostate cancer with [177Lu]DKFZ-PSMA-617","volume":"18","author":"Hohberg","year":"2016","journal-title":"Mol Imaging Biol"},{"issue":"8","key":"10.1053\/j.semnuclmed.2026.03.004_bib0039","first-page":"1003","article-title":"Reviving the acid phosphatase test for prostate cancer","volume":"21","author":"Al","year":"2007","journal-title":"Oncology"},{"issue":"Suppl. 2","key":"10.1053\/j.semnuclmed.2026.03.004_bib0040","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1097\/00000421-198801102-00012","article-title":"The usefulness of prostate-specific antigen and prostatic acid phosphatase in clinical practice","volume":"11","author":"Daver","year":"1988","journal-title":"Am J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2026.03.004_bib0041","doi-asserted-by":"crossref","unstructured":"Han M, Piantadosi S, Zahurak ML, et al. Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer. Urology 57(4):707-711, 2001.","DOI":"10.1016\/S0090-4295(00)01073-6"},{"key":"10.1053\/j.semnuclmed.2026.03.004_bib0042","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7090545","article-title":"Prostatic acid phosphatase (PAP) predicts prostate cancer progress in a population-based study: the renewal of Pap?","volume":"2019","author":"Xu","year":"2019","journal-title":"Dis Markers"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.03.004_bib0043","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1442-2042.2008.02029.x","article-title":"Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer","volume":"15","author":"Ozu","year":"2008","journal-title":"Int J Urol"},{"issue":"5","key":"10.1053\/j.semnuclmed.2026.03.004_bib0044","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011238","article-title":"Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach","volume":"13","author":"Cao","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"Supplement","key":"10.1053\/j.semnuclmed.2026.03.004_bib0045","article-title":"Annual Congress of the European Association of Nuclear Medicine 2025","volume":"1","year":"2025","journal-title":"EANM Innov"},{"issue":"11","key":"10.1053\/j.semnuclmed.2026.03.004_bib0046","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.2967\/jnumed.115.161299","article-title":"The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET\/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions","volume":"56","author":"Afshar-Oromieh","year":"2015","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2026.03.004_bib0047","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1053\/j.semnuclmed.2024.03.004","article-title":"Advances in PSMA Alpha Theragnostics","volume":"54","author":"Vorster","year":"2024","journal-title":"Semin Nucl Med."}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299826000619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299826000619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:29:40Z","timestamp":1792585780000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299826000619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0001299826000619"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2026.03.004","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The prostatic acid phosphatase in prostate cancer: A novel theranostic target","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2026.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}